Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28929680 | 0.86 | KDM4E (0.54) | IDO1TDO2BCDIN3DKDM4EPKM | |
| SCHEMBL3986190 | 0.85 | KDM4E (0.53) | IDO1TDO2BCDIN3DKDM4EPKM | |
| SCHEMBL12939727 | 0.84 | GRIN2B (0.52) | BCDIN3DKDM4EPKMGRIN2BGPR119 | |
| SCHEMBL3774389 | 0.82 | ALDH1A1 (0.55) | GPR119 | |
| SCHEMBL4050449 | 0.82 | KDM4E (0.51) | IDO1TDO2BCDIN3DKDM4EPKM | |
| SCHEMBL889008 | 0.81 | FPR3 (0.42) | IDO1TDO2BCDIN3DKDM4EPKM | |
| SCHEMBL15539667 | 0.81 | FPR2 (0.61) | IDO1TDO2KDM4EPKMGPR119 | |
| SCHEMBL386491 | 0.81 | GPR119 (0.50) | IDO1TDO2KDM4EPKMGRIN2B | |
| SCHEMBL15206132 | 0.81 | IDO1 (0.53) | IDO1TDO2BCDIN3DKDM4EPKM | |
| SCHEMBL5077936 | 0.80 | GPR119 (0.63) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | IDO1 2251/4885TDO2 647/4885BCDIN3D 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.